The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

International News

Indonesia in Bold Move to Obtain Cheap Drugs for HIV

October 16, 2012

On September 3, Indonesia's government quietly issued an order to override patents on seven important medicines used to treat individuals with HIV and hepatitis B, which will allow more inexpensive versions to be manufactured by local pharmaceutical companies. There appeared to be no protest from the pharmaceutical giants, who in the past would have defended their patents very aggressively. The drug patents belong to Merck, GSK, Bristol-Myers Squibb, Abbott, and Gilead. The drugs include Glaxo 's Abacavir, Abbott's Kaletra, and Gilead's tenofovir (Viread) which treats hepatitis B as well as providing the primary prevention treatment for those whose partners are HIV positive.

Indonesia's HIV incidence rate is not particularly high -- UNICEF estimates that nearly 310,000 individuals are infected -- but it does have the fourth highest population in the world and the virus continues to spread. Only approximately 23,000 of the 70,000 individuals infected with HIV who need drug treatment are getting it.

Back to other news for October 2012

Adapted from:
The Guardian (London)
10.11.2012; Sarah Boseley

  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
See Also
Indonesia Licenses Patents for Seven HIV and Hepatitis B Medicines
Indonesia and HIV/AIDS

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining: